Archimedes Pharma Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Archimedes Pharma Ltd.
Inivata Ltd., a cancer genomics company, has appointed Jeffrey Buchalter non-executive director and chair of its board. Most recently, Buchalter was CEO of Archimedes Pharma Ltd. and also received an award from the American Cancer Society for his commitment to cancer control and involvement in the oncology field. Buchalter has also been collaborating partner in the President's National Dialogue on Cancer and acted as chair of the board at National Childhood Cancer Foundation in the US.
Pharmalink of Sweden is basking in the "astonishingly good" Phase IIb data of Nefecon, its oral modified-release capsule of budesonide, in the treatment of primary IgA nephropathy – the most common form of glomerulonephritis. The NEFIGEN trial met its primary endpoint at a planned interim analysis and has been stopped early with respect to statistical analysis of the endpoint.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
Kyowa Hakko Kirin, via its subsidiary ProStrakan, is acquiring the UK's Archimedes Pharma for £230m ($393m) in a move that will significantly expand ProStrakan's reach across Europe.
- Specialty Pharmaceuticals
- Site Specific
- Other Names / Subsidiaries
- Archimedes Development Limited (ADL)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.